Altamira Therapeutics Ltd. (CYTO)
NASDAQ: CYTO · IEX Real-Time Price · USD
1.160
-0.180 (-13.43%)
At close: Jul 22, 2024, 8:58 AM
1.180
+0.020 (1.72%)
Pre-market: Jul 22, 2024, 9:15 AM EDT
Altamira Therapeutics Employees
Altamira Therapeutics had 10 employees as of December 31, 2023. The number of employees decreased by 6 or -36.20% compared to the previous year.
Employees
10
Change (1Y)
-6
Growth (1Y)
-36.20%
Revenue / Employee
n/a
Profits / Employee
-$442,900
Market Cap
2.69M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
TC Biopharm (Holdings) | 41 |
ASLAN Pharmaceuticals | 35 |
INVO Bioscience | 30 |
FOXO Technologies | 29 |
Helius Medical Technologies | 22 |
Tenon Medical | 21 |
Virax Biolabs Group | 11 |
Entero Therapeutics | 9 |
CYTO News
- 3 days ago - Altamira Therapeutics Announces Publication of Preclinical Data Showing Successful Treatment of Abdominal Aortic Aneurysm with SOD2 mRNA Delivered by SemaPhore Nanoparticles - GlobeNewsWire
- 4 weeks ago - Altamira Therapeutics Highlights Newly Published Review Article Supporting Use of Betahistine in Vertigo Management - GlobeNewsWire
- 7 weeks ago - Altamira Therapeutics Provides Business Update - GlobeNewsWire
- 2 months ago - Altamira Therapeutics Announces Dissemination of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis Through Social Media Channels of Top Allergy Journal - GlobeNewsWire
- 2 months ago - Altamira Therapeutics Announces Filing of Provisional Patent Application for OligoPhore Nanoparticles with siRNA Targeting p65 Protein in Treatment of Cancer and Inflammation - GlobeNewsWire
- 3 months ago - Altamira Therapeutics Announces Publication of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis in Top Peer Reviewed Journal - GlobeNewsWire
- 3 months ago - Altamira Therapeutics to Host Full Year 2023 Financial Results and Business Update Call on April 10, 2024 - GlobeNewsWire
- 4 months ago - Altamira Therapeutics Announces Collaboration with Univercells Group on Nanoparticle-Delivered mRNA Vaccines - GlobeNewsWire